Preclinical data suggest that MEK inhibition could promote hormone sensitivity in ovarian cancer cells; therefore, trials combining trametinib and aromatase inhibitors could be warranted in the future.30, 31. Here, MAP2K7 is linked to ovarian carcinoma.